Immunopathological disturbances in systemic sclerosis;Aspekty immuno-patologiczne twardziny układowej

Polski Merkuriusz Lekarski

Volumn 19, Issue 114, 2005, Pages 800-803

  Gindzienska Sieskiewicz, Ewa ^a   Klimiuk, Piotr Adrian ^a   Kowal Bielecka, Otylia ^a   Sierakowski, Stanisław ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Immunological disturbances; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; COLLAGEN; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

B LYMPHOCYTE; CELL ACTIVATION; CELL INFILTRATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONNECTIVE TISSUE DISEASE; CYTOKINE RELEASE; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; INFLAMMATORY CELL; ISCHEMIA; PATHOGENESIS; REVIEW; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; VASCULAR DISEASE;

AUTOANTIBODIES; FIBROBLASTS; HUMANS; LYMPHOCYTES; SCLERODERMA, SYSTEMIC;

EID: 30644457492     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Arnett F.C., Reveille J.D., Goldstein R. i wsp.: Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum., 1996, 39, 1151-1160.
2. Błaszczyk M., Jarza̧bek-Chorzelska M., Chorzelski T. i wsp.: Przeciwciała przeciw centromerom (ACA) i przeciw antygenowi Scl-70 - swoiste markery twardziny układowej. Przegl. Derm., 1986, 73, 185-190.
3. Boćko D.: Zaburzenia immunologiczne w przebiegu twardziny układowej. Nowa Klinika, 2001, 8, 1140-1143.
4. Bunn C.C., Black C.M.: Systemic sclerosis: an autoantibody mosaic. Clin. Exp. Immunol., 1999, 117, 207-208.
5. Degiannis D., Seibold J.R., Czarnecki M. i wsp.: Soluble and cellular markers of immune activation in patients with systemic sclerosis. Clin. Immunol. Immunopathol., 1990, 56, 259-270.
6. Diot E., Giraudeau B., Diot P. i wsp.: Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest, 1999, 116, 715-720.
7. Fritzler M.J., Kinsella T.D.: The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am. J. Med., 1980, 69, 520-526.
8. Fujimoto M., Sato S., Takehara K. i wsp.: Detection of antiribosomal P protein antibodies in patients with systemic sclerosis. Br. J. Rheumatol., 1995, 34, 908-911.
9. Gustafsson R., Totterman T.H., Klareskog L. i wsp.: Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis. Ann. Rheum. Dis., 1990, 49, 40-45.
10. Harvey G.R., Butts S., Rands A.L. i wsp.: Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin. Exp. Immunol., 1999, 117, 395-402.
11. Ihn H., Sato S., Fujimoto M. i wsp.: Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br. J. Rheumatol. 1998, 37, 1188-1192.
12. Ihn H., Yazawa N., Kubo M. i wsp.: Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J. Rheumatol., 2000, 27, 698-702.
13. Jabłońska S., Błaszczyk M., Jarza̧bek- Chorzelska M. i wsp.: Immunological markers of the subsets of systemic scleroderma and its overlap. Arch. Immunol. Then Exp., Warszawa, 1991, 39, 381-390.
14. Jimenez S.A., Hitraya E., Varga J.: Pathogenesis of scleroderma. Rheum. Dis. Clin. North Am., 1996, 22, 647-674.
15. Kahaleh M.B., LeRoy E.G.: Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann. Intern. Med., 1989, 110, 446-450.
16. Kawakami T., Ihn H., Xu W. i wsp.: Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J. Invest. Dermatol., 1998, 110, 47-51.
17. Kikuchi K., Kubo M., Sato S. i wsp.: Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J. Am. Acad. Dermatol., 1995, 33, 973-978.
18. Kopiński P., Nalepa P., Wojas-Pelc A. i wsp.: Zmiany w subpopulacjach limfocytów w płynie z płukania oskrzelowo-pȩcherzykowego u chorych na twardzinȩ układowa̧. Pol. Merk. Lek., 2000, 8, 18-22.
19. Labrador M., Alguero A., Diaz C. i wsp.: Antibodies against a novel nucleolar and cytoplastic antigen (p105-p42) present in the sera of patients with a subset of rheumatoid arthritis (RA) with signs of scleroderma. Clin. Exp. Immunol., 1998, 114, 301-310.
20. Lee Y.J., Shin K.C., Kang S.W. i wsp.: Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis. Clin. Exp. Rheumatol., 2001, 19, 69-74.
21. LeRoy E.G.: Systemic sclerosis. A vascular perspective. Rheum. Dis. Clin. North Am., 1996, 22, 675-694.
22. Lis A., Brzezińska-Wcisło L., Rubisz-Brzezińska J. i wsp.: Serum levels of soluble interleukin-2 receptor - a possible index of disease prognosis in systemic sclerosis. Clin. Exp. Dermatol., 1997, 22, 60-61.
23. Matsui T., Kurokawa M., Kobata T. i wsp.: Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J. Immunol., 1999, 162, 4328-4335.
24. Maul G.G., French B.T., van Venrooij W.J. i wsp.: Topoisomerase I identified by scleroderma 70 antisera: Enrichment of topoisomerase I at the centromere in mose mitotic cells before anaphase. Proc. Natl. Acad. Sci., USA 1986, 83, 5145-5149.
25. McHugh N.J., Distler O., Giacomelli R. i wsp.: Non organ based laboratory markers in systemic sclerosis. Clin. Exp. Rheumatol., 2003, 21 (Suppl. 29), 32-S38.
26. Mitri G.M., Lucas M., Fertig N. i wsp.: A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum., 2003, 48, 203-209.
27. Moroi Y., Peebles C., Fritzler M.J. i wsp.: Autoantibody to centromere (kinetochore) in scleroderma sera. Proc. Natl. Acad. Sci., USA 1980, 77, 1627-1631.
28. Okano Y.: Antinuclear antibody in systemic sclerosis (scleroderma). Rheum. Dis. Clin. North Am. 1996, 22, 709-735.
29. Ożóg-Sulikowska A.: Przeciwciała przeciwjadrowe w układowych chorobach tkanki la̧cznej. Nowa Klinika, 2001, 8, 1144-1152.
30. Puszczewicz M.J.: Przeciwciała przeciwja̧drowe w diagnostyce różnicowej chorób układowych. Reumatologia, 1998, 36, 30-41.
31. Roumm A.D., Whiteside T.L., Medsger T.A. Jr. i wsp.: Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum., 1984, 27, 645-653.
32. Russo K., Hoch S., Dima C. i wsp.: Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. J. Rheumatol., 2000, 27, 142-148.
33. Sakkas L.I., Tourtellotte C., Berney S. i wsp.: Increased levels of alternatively spliced interleukin 4 (IL-4 delta2) trancripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin. Diagn. Lab. Immunol., 1999, 6, 660-664.
34. Samuels D.S., Tojo T., Homma M. i wsp.: Inhibition of topoisomerase I by antibodies in sera from scleroderma patients. FEBS Lett., 1986, 209, 231-234.
35. Sato S., Nagaoka T., Hasegawa M. i wsp.: Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: associations with extent of skin sclerosis and severity of pulmonary fibrosis. J. Rheumatol., 2000, 27, 149-154.
36. Sierakowski S., Bernacka K.: Humoral and cellular immunity in progressive systemic sclerosis. Med. Interne, 1987, 25, 233-238.
37. Sierakowski S.J., Kucharz E.J.: Zaburzenia odporności komórkowej w twardzinie uogólnionej. Przegl. Lek., 1988, 45, 592-597.
38. Sierakowski S., Kowal-Bielecka O., Gindzieńska-Sieśkiewicz E.: Twardzina układowa. Reumatologia, 2004, 42 (Suppl. 1), 59-69.
39. Steen V.D., Engel E.E., Charley M.R. i wsp.: Soluble serum interleukin 2 receptors in patients with systemic sclerosis. J. Rheumatol., 1996, 23, 646-649.
40. Valentini G., Silman AJ., Veale D.: Assessment of disease activity. Clin. Exp. Rheumatol., 2003, 21 (Suppl. 29), 39-S41.
41. Weiner E.S., Hildebrandt S., Senecal J.L. i wsp.: Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum., 1991, 34, 68-77.
42. Wetzig T., Petri J.B., Mittag M. i wsp.: Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis. Arch. Dermatol. Res., 1998, 290, 187-190.
43. White B.: Immunopathogenesis of systemic sclerosis. Rheum. Dis. Clin. North Am. 1996, 22, 695-708.
44. Wisłowska M.: Patogeneza i leczenie twardziny układowej. Reumatologia 2003, 41, 160-176.
45. Yamane K., Ihn H., Kubo M. i wsp.: Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J. Rheumatol. 2000, 27, 930-934.